Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years

Seminars in Hematology

Volumn 50, Issue 1, 2013, Pages 4-14

  Vassilakopoulos, Theodoros P ^a   Angelopoulou, Maria K ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; NEOPLASM RECURRENCE, LOCAL;

EID: 84875299063     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.02.002     Document Type: Article

References (95)

1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832, 17:69-97.
2. Bonadonna G. Historical review of Hodgkin's disease. Br J Haematol 2000, 110:504-511.
3. De Vita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970, 73:891-895.
4. Longo D.L., Young R.C., Wesley M., et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986, 4:1295-1306.
5. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
6. Bonadonna G. Chemotherapy strategies to improve the control of Hodgkin's disease. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1982, 42:4309-4320.
7. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
8. Canellos G.P., Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2009, 361:2390-2391.
9. Vassilakopoulos T.P., Angelopoulou M.K., Siakantaris M.P., et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001, 67:279-288.
10. Viviani S., Bonadonna G., Santoro A., et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996, 14:1421-1430.
11. Johnson P.W.M., Radford J.A., Cullen M.H., et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). J Clin Oncol 2005, 23:9208-9218.
12. Connors J.M., Klimo P., Adams G., et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997, 15:1638-1645.
13. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial. J Clin Oncol 2003, 21:607-614.
14. Ferme C., Sebban C., Hennequin C., et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des lymphomas de l'Adulte H89 trial. Blood 2000, 95:2246-2252.
15. Gobbi P.G., Levis A., Chisesi T., et al. ABVD vs. modified Stanford V vs. MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005, 23:9198-9207.
16. Federico M., Luminari S., Ianitto E., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. J Clin Oncol 2009, 27:805-811.
17. Sieber M., Tesch H., Pfistner B., et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004, 15:276-282.
18. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.
19. Hoskin P.J., Lowry L., Horwich A., et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009, 27:5390-5396.
20. Gordon L.I., Hong F., Fisher R.I., et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) [Abstract]. J Clin Oncol 2013, 31:684-691.
21. Tesch H., Diehl V., Lathan B., et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998, 92:4560-4567.
22. Loeffler M., Hasenclever D., Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. Ann Oncol 1998, 9(Suppl 5):S73-S78.
23. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
24. Engert A., Diehl V., Franklin J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009, 20:4548-4554.
25. Borchmann P., Haverkamp H., Diehl V., et al. Eight cycles of escalated dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011, 29:4234-4242.
26. Engert A., Haverkamp H., Kobe C., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012, 379:1791-1799.
27. Viviani S., Zinzani P.L., Rambaldi A., et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011, 365:203-212.
28. Borchmann P., Rancea M., Haverkamp H., Diehl V., Skoetz N., Engert A. First line treatment of advanced stage Hodgkin lymphoma with six cycles of BEACOPP escalated results in superior overall survival compared to ABVD: results of a network meta-analysis including 10,011 patients. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 551.
29. Advani R. Optimal therapy of advanced Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2011, 310-316.
30. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998, 339:1506-1514.
31. Vassilakopoulos T.P., Angelopoulou M.K., Siakantaris M.P., et al. Validation of the International Prognostic Score in patients with advanced Hodgkin's lymphoma treated in a single hematology unit. Haema 2001, 4:230-235.
32. Guisado-Vasco P., Arranz-Saez R., Canales M., et al. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score (IPS) for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leuk Lymphoma 2012, 53:812-819.
33. Moccia A.A., Donaldson J., Chhanabhai M., et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 2012, 30:3383-3388.
34. Gobbi P.G., Ghirardelli M.L., Solcia M., et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001, 19:1388-1394.
35. Vassilakopoulos T.P., Pangalis G.A. Biological prognostic factors in Hodgkin's lymphoma. Haema 2004, 7:147-164.
36. Hsi E.D. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008, 49:1668-1680.
37. Sanchez-Espiridion B., Garcia J.F., Sanchez-Beato M. Advances in classical Hodgkin lymphoma biology: new prognostic factors and outcome prediction using gene expression signatures. Hodgkin lymphoma 2012, 29-46. In Tech. http://www.intechopen.com/books/hodgkin-s-lymphoma, N. Rezaei (Ed.).
38. Scott D.W., Chan F.C., Hong F., et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced stage classical Hodgkin lymphoma. J Clin Oncol 2012, Epub Nov 26.
39. Sarris A.H., Kliche K.O., Pethambaram P., et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999, 10:433-440.
40. Vassilakopoulos T.P., Nadali G., Angelopoulou M.K., et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001, 86:274-281.
41. Visco C., Nadali G., Vassilakopoulos T.P., et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006, 77:387-394.
42. Casasnovas R.O., Mounier N., Brice P., et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007, 25:1732-1740.
43. Rassidakis G.Z., Medeiros L.J., Vassilakopoulos T.P., et al. Bcl-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002, 100:3935-3941.
44. Sanchez-Espiridion B., Montalban C., Lopez A., et al. A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma. Blood 2010, 116:e12-e17.
45. Chetaille B., Bertucci F., Finetti P., et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113:2765-2775.
46. Steidl C., Lee T., Shah S., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
47. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
48. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
49. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826.
50. Piccaluga P.P., Agostinelli C., Gazzola A., et al. Pathobiology of Hodgkin lymphoma. Adv Hematol 2011, Article ID 920898.
51. Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2012, 328-334.
52. Meignan M., Gallamini A., Haioun C., Polliack A. Report on the Second International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010, 51:2171-2180.
53. Gallamini A., Kostakoglou L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?. Blood 2012, 120:4913-4920.
54. Gallamini A., Patti C., Viviani S., et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011, 152:551-560.
55. Aleman B.M.P., Raemaekers J.M.M., Tirelli U., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003, 348:2396-2406.
56. Vassilakopoulos T.P., Pangalis G.A., Boutsikas G., et al. Prognostic factors in patients with Hodgkin lymphoma (HL) and a negative PET/CT after ABVD chemotherapy: potential applications for the design of follow-up strategies [abstract 218]. Haematol Hematol J 2012, 97(Suppl 1):87.
57. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2001, 20:221-230.
58. Bonadonna G., Santoro A., Gianni M., et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1991, 2(suppl 1):9-16.
59. Josting A., Nogova L., Franklin J., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005, 23:1522-1529.
60. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000, 18:2615-2619.
61. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079.
62. Santoro A., Magagnoli M., Spina M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007, 92:35-41.
63. Baetz T., Belch A., Couban S., et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003, 14:1762-1767.
64. Vassilakopoulos T.P., Angelopoulou M.K., Siakantaris M.P., et al. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. Eur J Haematol 2002, 68:289-298.
65. Bonfante V., Santoro A., Viviani S., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997, 15:528-534.
66. Josting A., Rueffer U., Franklin J., et al. Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000, 96:1280-1286.
67. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
68. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
69. Josting A., Muller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010, 28:5074-5080.
70. André M., Henry-Amar M., Pico J.L., et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Française de Greffe de Moëlle. J Clin Oncol 1999, 17:222-229.
71. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999, 17:534-545.
72. Moskowitz A.J., Perales M.A., Kewalramani T., et al. Outcomes for patients who fail high-dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009, 146:158-163.
73. Horning S., Fanale M., deVos S., et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008, 19:118.
74. Vassilakopoulos T.P., Pangalis G.A., Boutsikas G., et al. Hodgkin lymphoma (hl) in patients ≥60 years old: clinical and laboratory features, outcome after anthracycline-based treatment and comparison with younger patients: a single center experience [abstract 320]. Haematol Hematol J 2011, 96(Suppl 2):87.
75. Boll B., Gorgen H., Arndt N., et al. Relapsed Hodgkin lymphoma in elderly patients: a comprehensive analysis from the German Hodgkin Study Group (GHSG) [abstract 92]. Blood (ASH Annual Meeting Abstracts) 2011, 118.
76. Thomson K.J., Peggs K.S., Blundell E., Goldstone A.H., Linch D.C. A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma 2007, 48:881-884.
77. Smith S.M., van Besien K., Carreras J., et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008, 14:904-912.
78. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
79. Forero-Torres A., Leonard J.P., Younes A., et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.
80. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009, 13:235-244.
81. Katz J., Janik J.E., Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011, 17:6428-6436.
82. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
83. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
84. Chen R.W., Gopal A.K., Smith S.E., et al. Long-term survival analyses of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [abstract 624]. Blood (ASH Annual Meeting Abstracts) 2012, 120.
85. + hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012, 120:1470-1472.
86. Chen R.W., Palmer J., Siddiqi T., et al. Brentuximab Vedotin as first line salvage therapy in relapsed/refractory HL [abstract 3699]. Blood (ASH Annual Meeting Abstracts) 2012, 120.
87. Forero-Torres A., Fanale M., Advani R., et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012, 17:1073-1080.
88. Rothe A., Sasse S., Goergen H., et al. Brentuximab vedotin (SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation [abstract 2743]. Blood (ASH Annual Meeting Abstracts) 2012, 120.
89. Smith S., Chen R., Gopal A., et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract 1109]. Haematol Hematol J 2012, 97(suppl 1).
90. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity haematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
91. Forero-Torres A., Brice P., Chen R., et al. Retreatment with brentuximab vedotin in CD30 positive hematologic malignancies: a phase 2 study [abstract 213]. Haematol Hematol J 2012, 97(suppl 1).
92. Forero-Torres A., Berryman B.R., Advani R.H., et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [abstract 3711]. Blood (ASH Annual Meeting Abstracts) 2011, 118.
93. Gopal A.K., Ramchandren R., O' Connor O.A., et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplasntation. Blood 2012, 120:560-568.
94. Ansell S.M., Connors J.M., Park S.I., O' Meara M.M., Younes A. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma [abstract 798]. Blood (ASH Annual Meeting Abstracts) 2012, 120.
95. Brenner H., Gondos A., Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008, 111:2977-2983.